SNBL Revamps Top Management to Drive Long-Term Growth

Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) just unveiled an announcement.

Shin Nippon Biomedical Laboratories has announced a leadership reshuffle, appointing Hideyuki Hirama as Representative President while long-serving leader Ryoichi Nagata will become Representative Chairman, effective after shareholder approval at the June 26, 2026 annual meeting. The move is aimed at strengthening the management structure to support sustainable medium- to long-term growth, and is accompanied by an expanded board slate, the promotion of Masato Nishie as a corporate officer, and the appointment of Naohiro Tsubaru as Honorary Senior Director.

Hirama brings experience from Mizuho Financial Group, SNBL USA, Gemseki Inc., and Rakuten Group’s Rakuten Symphony unit, indicating a push to blend financial, operational, and digital expertise in the next phase of the company’s development. The refreshed governance lineup, with both reappointed and newly appointed directors and officers, underscores SNBL’s intention to reinforce oversight and strategic capabilities as it pursues greater corporate value and potentially more competitive positioning in the biomedical services market.

The most recent analyst rating on (JP:2395) stock is a Buy with a Yen1780.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.

More about Shin Nippon Biomedical Laboratories, Ltd.

Shin Nippon Biomedical Laboratories, Ltd., listed on the TSE Prime, operates in the biomedical and pharmaceutical services sector. The company provides drug discovery and preclinical research-related services, positioning itself as a partner to pharmaceutical and life science firms seeking to advance R&D and enhance long-term corporate value.

Average Trading Volume: 224,483

Technical Sentiment Signal: Sell

Current Market Cap: Yen59.2B

See more insights into 2395 stock on TipRanks’ Stock Analysis page.